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Although recurrent gene fusions involving erythroblastosis virus E26 transformation-specific (ETS) family transcription factors are common in prostate cancer, their products are considered 'undruggable' by conventional approaches. Recently, rare targetable gene fusions involving the anaplastic lymphoma receptor tyrosine kinase (ALK) gene, have been identified in 1-5% of lung cancers 1 , suggesting that similar rare gene fusions may occur in other common epithelial cancers, including prostate cancer. Here we used paired-end transcriptome sequencing to screen ETS rearrangementnegative prostate cancers for targetable gene fusions and identified the SLC45A3-BRAF (solute carrier family 45, member 3-v-raf murine sarcoma viral oncogene homolog B1) and ESRP1-RAF1 (epithelial splicing regulatory protein-1-v-raf-1 murine leukemia viral oncogene homolog-1) gene fusions. Expression of SLC45A3-BRAF or ESRP1-RAF1 in prostate cells induced a neoplastic phenotype that was sensitive to RAF and mitogen-activated protein kinase kinase (MAP2K1) inhibitors. Screening a large cohort of patients, we found that, although rare, recurrent rearrangements in the RAF pathway tend to occur in advanced prostate cancers, gastric cancers and melanoma. Taken together, our results emphasize the key role of RAF family gene rearrangements in cancer, suggest that RAF and MEK inhibitors may be useful in a subset of gene fusion-harboring solid tumors and demonstrate that sequencing of tumor transcriptomes and genomes may lead to the identification of rare targetable fusions across cancer types.
Recurrent gene fusions characterized by 5′ genomic regulatory elements (most commonly controlled by androgens) fused to members of the ETS family of transcription factors are present in at least half of all prostate cancers 2, 3 . Unfortunately, such rearrangements involving oncogenic transcription factors are considered poor therapeutic targets by conventional pharmaceutical approaches, owing to lack of enzymatic activity, inaccessibility in the nucleus and requirement of interaction with other proteins to achieve specificity. The recent identification of rearrangements involving a protein kinase (EML4-ALK) in a rare subset of non-small-cell lung carcinomas, and preclinical and phase 1 and 2 clinical data suggesting that people with such rearrangements respond to investigational ALK inhibitors 1, 4 , demonstrates that rare druggable rearrangements may exist in small subsets of patients with common solid tumors.
To search for such druggable rearrangements in prostate cancer, we used paired-end, massively parallel transcriptome sequencing to prioritize candidate gene fusions in prostate tumors by generating a score derived from the quantity of mate-pair reads that meet a series of computational filters implemented to reduce potential false-positive chimera nominations 5 . Prioritization histograms for two ETS rearrangement-positive prostate cancers, PCA1 and PCA2, which harbor AX747630 (Homo sapiens cDNA FLJ35294 fis, clone PROST2008724)-ETV1 and TMPRSS2-ERG (transmembrane protease, serine 2-v-ets erythroblastosis virus E26 oncogene homolog (avian)) gene fusions, respectively, indicate that the ETS gene fusion had the highest score in each sample (Fig. 1a) , as we have reported previously 5, 6 .
In this study, we sequenced five ETS gene fusion-positive and ten ETS gene fusion-negative prostate cancers (ETS gene fusion status was determined by fluorescence in situ hybridization (FISH), quantitative RT-PCR (qRT-PCR) or both) and found that two ETS-negative samples, PCA3 and PCA17, each prioritized a fusion involving BRAF and RAF1 genes, key serine-threonine kinase components of the RAF signaling pathway (Fig. 1a) .
Whereas activating somatic mutations in the RAF kinase pathway, such as BRAF with a mutation that results in a V600E amino acid substitution (BRAF V600E ), are common in melanoma, thyroid, colon and ovarian cancers [7] [8] [9] [10] , activating gene fusions of pathway members have been reported less frequently and are found in subsets of relatively rare cancers [11] [12] [13] . Notably, the RAF kinase pathway is druggable, with multiple approved and investigational agents in late-stage development. Sorafenib, a US Food and Drug Administration-approved drug, was originally identified as a RAF kinase inhibitor but was subsequently found to target other kinases such as vascular endothelial growth factor receptor-2 (VEGFR-2), VEGFR-3 and platelet-derived growth factor receptor-β 14 . An emerging lead drug candidate, PLX-4032, seems to be highly selective for the BRAF V600E mutation and is being evaluated in people with advanced melanoma 15 . Thus, we proceeded to characterize and validate the potentially druggable gene fusions we identified in prostate tumors PCA3 and PCA17.
The first case, PCA3, revealed an interchromosomal rearrangement resulting in the fusion of untranslated exon 1 of SLC45A3 with exon 8 of BRAF (Fig. 1b) . Notably, SLC45A3 is a prostate-specific, androgen responsive gene that has been found fused to ERG 16, 17 , ETV1 18 , ETV5 19 and ELK4 20, 21 in a subset of prostate tumors. The predicted open reading frame encodes 329 amino acids of the C-terminal portion of BRAF ( Supplementary  Fig. 1a) , retaining the kinase domain but losing the N-terminal RAS-binding domain, suggesting that the mutant protein may be constitutively active. Having inherited promoter regulatory elements from SLC45A3, this BRAF fusion is probably under androgen regulation (Supplementary Fig. 2 ). Consistent with this, the C-terminal exons of BRAF (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) present in the fusion protein are overexpressed in PCA3 tumor relative to normal prostate and other prostate cancers ( Supplementary Fig. 3a,b) . The second case, PCA17, revealed two highly expressed gene fusions involving ESRP1 and RAF1 (Fig. 1c,d) , presumably formed by a balanced reciprocal translocation. ESRP1 is a splicing factor that regulates the formation of epithelial cell-specific isoforms of mRNA 22 , whereas RAF1 (or CRAF) is a serine-threonine protein kinase.
The ESRP1-RAF1 fusion transcript involves the fusion of exon 13 of ESRP1 to exon 6 of RAF1 (Fig. 1c) . The predicted open reading frame encodes a 120-kDa fusion protein comprised of the majority of ESRP1, including its three RNA recognition motifs, fused to the C-terminal kinase domain of RAF1 (Supplementary Fig. 1c) . Loss of the RAS-binding domain of RAF1 suggests that this fusion protein may be constitutively active, whereas the role of the RNAbinding domains of ESRP1 is unclear.
In addition to ESRP1-RAF1, we also detected the reciprocal gene fusion RAF1-ESRP1, produced from the same genomic rearrangement in PCA17. The RAF1-ESRP1 transcript involves the fusion of exon 5 of RAF1 with exon 14 of ESRP1 (Fig. 1d) , which encodes a predicted 30-kDa protein comprised of the RAS-binding domain of RAF1 fused to 194 amino acids from the C terminus of ESRP1 ( Supplementary  Fig. 1c ). Unlike SLC45A3-BRAF, ESRP1-RAF1 is predicted to not be regulated by androgen, as wild-type ESRP1 is not androgen regulated ( Supplementary Fig. 2) .
Next, the SLC45A3-BRAF fusion was confirmed by fusion-specific qPCR in PCA3 tumor. Rearrangement at the DNA level was validated by FISH and confirmed the presence of two copies of rearranged chromosomes by break-apart ( Supplementary Fig. 4a ) and fusion ( Fig. 2) assays. Expression of the SLC45A3-BRAF fusion gene in HEK293 cells and stable expression in RWPE (human benign immortalized prostate epithelial cell line) cells generated a 37-kDa protein ( Supplementary Fig. 5a,b) .
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Chr. 3p25.1 Similarly, ESRP1-RAF1 and RAF1-ESRP1 were validated by qRT-PCR (Fig. 2b) in the index PCA17 tumor. FISH confirmed the DNAlevel rearrangement and fusion of the ESRP1 and RAF1 loci ( Fig. 2d  and Supplementary Fig. 4b ). Expression of a 120-kDa ESRP1-RAF1 fusion protein was observed in PCA17 tumor and upon overexpression in HEK293 (Fig. 2g) and RWPE cells (Supplementary Fig. 5c ).
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We estimated BRAF and RAF1 rearrangement frequencies in three independent prostate cancer clinical cohorts by FISH on tissue microarrays with break-apart probes. Out of 349 prostate cancer cases that were evaluable by FISH, six cases had an aberration at the BRAF locus (five rearrangements and one deletion of the 5′ probe), and four of 450 cases showed rearrangement at the RAF1 locus (one rearrangement and three deletions of the 3′ probe). Other than the index cases PCA3 and PCA17, these cases did not show rearrangement of the SLC45A3 or ESRP1 loci, suggesting fusions involving multiple 5′ partners, similar to ETV1 fusions in prostate cancer 18 . Owing to the lack of availability of frozen tissue, we were unable to characterize the 5′ fusion partners in these specific cases. Notably, a majority of the cases that were positive for rearrangements of BRAF or RAF1 had advanced features including high Gleason score and castration resistance. All of the cases were negative for ETS gene rearrangement (except MET37, which had an ERG rearrangement), suggesting that these aberrations occur predominantly in ETS-negative prostate cancers (Supplementary Table 1a) .
We extended the analysis of BRAF and RAF1 rearrangements to other solid tumors by using break-apart FISH probes on tissue microarrays of breast (n = 49), endometrial (n = 26), gastric (n = 85), melanoma (n = 131) and liver (n = 42) tumors. Similar to the case in prostate cancer, we found a 1-2% incidence of BRAF aberrations in gastric cancer (2 of 105) (Fig. 2e) and one case each of BRAF and RAF1 rearrangement in melanoma (2 of 131) (Fig. 2f) . In the gastric cancer index case GCT-15, paired-end transcriptome sequencing revealed that exon 8 of the BRAF gene was fused with exon 5 of AGTRAP (encoding angiotensin II, type I receptor-associated protein) (Fig. 1e) . We validated the AGTRAP-BRAF fusion transcript by qRT-PCR (Fig. 2c) and the DNA-level rearrangement by FISH analysis (Fig. 2f) . The AGTRAP-BRAF fusion resulted in the formation of a 597-amino acid fusion protein with the C-terminal kinase domain of BRAF fused to the N-terminal angiotensin II, type 1 receptor-associated domain of AGTRAP (Supplementary Fig. 1d) . We confirmed the expression of the predicted AGTRAP-BRAF fusion protein by immunoblot analysis of the index tumor GCT-15 (Fig. 2h) . The 5′ partner genes for the second gastric case with BRAF-rearrangement-positive and BRAF-and RAFrearrangement-positive melanoma cases were not confirmed owing to the lack of frozen tissue (Supplementary Table 1b) .
Considering the prevalence of oncogenic mutations in BRAF in various cancer types, we screened for the BRAF V600E mutation by 
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P C A 2 1 P C A 2 2 P C A 2 3 P C A 2 4 P C A 2 5 We found that 20 of 34 (59%) melanoma samples, one of 25 gastroesophageal cancers and zero of 274 prostate samples were positive for the BRAF V600E mutation (data not shown). Of note, none of the RAF pathway gene rearrangement-positive prostate cancers, gastroesophageal cancers and melanomas identified herein harbored Val600 mutations, suggesting genomic rearrangement, rather than mutation, as a mechanism for RAF gene activation in a subset of solid tumors.
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In an Asian cohort, 10% of prostate cancer cases have been reported to be positive for BRAF V600E mutations 23 . We were unable to find any BRAF Val600 mutations in our prostate cancer cohorts, which is consistent with a recently published study (zero of 95 prostate cancers were positive for Val600) 24 .
We next examined the functional relevance of the fusions involving RAF pathway members in prostate cancer. First, we examined the SLC45A3-BRAF fusion in mouse fibroblast NIH3T3 cells, a system classically used to study RAS and RAF biology 25 . Overexpression of SLC45A3-BRAF (Supplementary Fig. 1b) or mutant BRAF V600E showed a marked increase in the number of foci as compared to vector controls (Fig. 3a) . The foci assay data were further validated by automated colony counting (Supplementary Fig. 6a ). NIH3T3 cells overexpressing SLC45A3-BRAF formed rapidly growing tumors in nude mice (Fig. 3b) ; however, NIH3T3 cells overexpressing ESRP1-RAF1 did not form tumors (data not shown), which may reflect signaling differences between the different fusion products. To examine the role of these fusions in the prostate, we overexpressed SLC45A3-BRAF or ESRP1-RAF1 in RWPE cells; both gene fusions resulted in increased cell proliferation that was sensitive to the RAF kinase inhibitor sorafenib (Fig. 3c,d) . We also observed a marked increase in cell invasion of RWPE cells expressing either SLC45A3-BRAF or ESRP1-RAF1, which was sensitive to sorafenib or the MEK inhibitor U0126 (Fig. 4a,b) . Furthermore, RWPE cells expressing either SLC45A3-BRAF or ESRP1-RAF1 formed anchorageindependent colonies in soft agar, which were again sensitive to RAF and MEK inhibitors (Fig. 4c,d) . Finally, RWPE cells stably expressing SLC45A3-BRAF formed small tumors in immunodeficient mice that regressed after 4 weeks (Supplementary Fig. 6b) .
The RAF family is known to have a pivotal role in transducing signals from RAS to downstream kinases, mitogen-activated protein kinase and extracellular signal-regulated kinase (ERK) kinase (MEK1/2) and ERK1/2 (ref. 26) . As expected, overexpression of SLC45A3-BRAF or ESRP1-RAF1 in RWPE cells induced MEK and ERK phosphorylation, which was sensitive to treatment with a MEK inhibitor (Fig. 4e) . The MEK inhibitor also decreased MEK1/2 and ERK1/2 phosphorylation in a control BRAF V600E mutation-positive human melanoma cell line, SK-MEL-94, consistent with previous data 27 . We also found an increase in mRNA expression of genes encoding the feedback effectors dual-specificity phosphatase-6 and sprouty homolog-2 (ref. 27) in RWPE cells stably expressing SLC45A3-BRAF or ESRP1-RAF1, and the expression of these feedback effectors was decreased upon MEK inhibitor treatment (Supplementary Fig. 7) .
Our results emphasize the key role of the RAF pathway in prostate cancer development and progression. Although it is rare (possibly nonexistent) in human prostate tumors, activation of the BRAF pathway via the V600E mutation in genetically engineered mice has been shown to cooperate with other lesions to initiate the development of invasive prostate cancer 28 . This model may now have greater clinical significance in comparing response to treatment in a subtype of patients for the study of human prostate cancer. Finally, ETS transcription factors, including ETV1, have been shown to be downstream targets activated by the RAS-RAF-MAPK signaling pathway 29, 30 , suggesting a possible common pathway.
Sequencing tumor transcriptomes and genomes may identify rare targetable fusions across cancer types. Screening for RAF kinase fusions may be useful in identifying people with cancer who may benefit from treatment with RAF kinase inhibitors, similar to what is already being considered clinically for ALK fusions in lung cancer. Our identification of RAF pathway gene rearrangements in 1-2% of prostate cancers, gastric cancers and melanomas (and earlier work by others in rarer cancers [7] [8] [9] [10] [11] [12] [13] ) supports the general principle that cancers should be classified by driving molecular events, rather than by organ site, in the context of rational targeted therapy.
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